Clinical trials: Tace
Carcinoma, Hepatocellular
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol…
- Trial name
- NCT00857805
- Testing
- Transarterial Chemoembolization, Proton Beam Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Loma Linda University
Hepatocellular Carcinoma Non-resectable
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len)…
- Trial name
- NCT04967495
- Testing
- TACE combined with lenvatinib and iodion-125 seeds brachytherapy, TACE combined with lenvatinib
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Abstract of Research Proposal Radiofrequency ablation (RFA) has been proved to be a curative treatment with minimal invasiveness and high efficacy for small hepatocellular carcinoma (HCC) that is generally defined as maximal…
- Trial name
- NCT01858207
- Testing
- Transcatheter Arterial Chemoembolization, Radiofrequency ablation, Doxorubicin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Shi-Ming Lin
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide…
- Trial name
- NCT05647954
- Testing
- HX008 + TACE, Temozolomide + TACE, Pembrolizumab
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Hepatocellular Carcinoma (HCC)
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
This study is a prospective, single-arm, phase Ⅱtrial. The subjects are patients resectable centrally-located hepatocellular carcinoma in BCLC stage B who are admitted to the Hepatobiliary Surgery Department of Tongji Hospital …
- Trial name
- NCT07154082
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Wei Zhang
Carcinoma, Hepatocellular
Adjuvant TACE to Reduce the HCC Recurrence After Resection
Hepatocellular carcinoma (HCC) is the sixth most common malignancies worldwide and the second leading cause of cancer-related death.
- Trial name
- NCT02788526
- Testing
- Adjuvant TACE, Follow-up
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with…
- Trial name
- NCT06353126
- Testing
- DEB-TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Colorectal Adenocarcinoma Metastatic to the Liver
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)
To date no randomized controlled trials have been completed that demonstrated whether TACE(Transarterial chemoembolization) is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in…
- Trial name
- NCT03783559
- Testing
- TACE, chemotherapy±target therapy
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma by BCLC Stage
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond…
- Trial name
- B-TACE (NCT05883176)
- Testing
- Bevacizumab Biosimilar QL 1101
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Hepatocellular Carcinoma
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Hepatocellular carcinoma (HCC) is one of the tumors with an increasing incidence worldwide. Often treatment possibilities are limited and only palliative treatment such as a transarterial chemoembolisation (TACE) is possible.
- Trial name
- NCT01360255
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Freiburg
Hepatocellular Carcinoma, Hepatocellular Cancer
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
To determine the maximum tolerated radiation dose with concurrent sorafenib for unresectable hepatocellular carcinoma that has not responded to transarterial chemoembolization.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
- Trial name
- NCT01618253
- Testing
- Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Thrombocytopenia, Hepatocellular Carcinoma
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion…
- Trial name
- NCT06001567
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC), Artificial Intelligent
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although curative surgical resection improves survival for early-stage HCC patients, the 5-year postoperative recurrence…
- Conditions
- Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACE
- Trial name
- NCT07417800
- Testing
- AI adjuvant therapy
- Where
- China
- Volunteers
- 11,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .
- Trial name
- NCT03510416
- Testing
- Apatinib, TACE
- Volunteers
- 22 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
This is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of PVL/PVE combined with DEB-TACE in the treatment of unresectable patients with large or…
- Trial name
- CCGLC-004 (NCT05103007)
- Testing
- DEB-TACE, PVL/PVE+DEB-TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation
Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered.
- Trial name
- CELPerCutCHC (NCT04813861)
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Central Hospital, Nancy, France
Early Hepatocellular Carcinoma
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
This Phase II Prospective, parallel and open-label randomised control trial will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use…
- Trial name
- SOCRATES HCC (NCT07628751)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR), Therapies
- Where
- 2 sites in Australia, Canada
- Volunteers
- 218 people
- Sponsor
- University Health Network, Toronto